ATE135234T1 - Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus - Google Patents

Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus

Info

Publication number
ATE135234T1
ATE135234T1 AT88310800T AT88310800T ATE135234T1 AT E135234 T1 ATE135234 T1 AT E135234T1 AT 88310800 T AT88310800 T AT 88310800T AT 88310800 T AT88310800 T AT 88310800T AT E135234 T1 ATE135234 T1 AT E135234T1
Authority
AT
Austria
Prior art keywords
thrombo
embolism
inhibition
thrombotic occlusion
arterial thrombotic
Prior art date
Application number
AT88310800T
Other languages
English (en)
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135234(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Application granted granted Critical
Publication of ATE135234T1 publication Critical patent/ATE135234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT88310800T 1987-11-17 1988-11-16 Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus ATE135234T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (1)

Publication Number Publication Date
ATE135234T1 true ATE135234T1 (de) 1996-03-15

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88310800T ATE135234T1 (de) 1987-11-17 1988-11-16 Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus

Country Status (11)

Country Link
US (2) US5084274A (de)
EP (1) EP0318201B1 (de)
JP (1) JP2766986B2 (de)
AT (1) ATE135234T1 (de)
CA (1) CA1330036C (de)
DE (1) DE3855096T2 (de)
DK (1) DK175704B1 (de)
ES (1) ES2086301T3 (de)
FI (1) FI104790B (de)
GR (1) GR3020036T3 (de)
NO (1) NO301747B1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE69032029T2 (de) * 1989-12-29 1998-08-20 Zymogenetics Inc Hybrides protein c
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
DE59204945D1 (de) * 1991-04-16 1996-02-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US6143719A (en) * 1995-06-09 2000-11-07 The Regents Of The University Of Michigan Bradykinin analogs as selective thrombin inhibitors
JP4680329B2 (ja) * 1997-03-24 2011-05-11 カーディオム ファーマ コーポレイション 血管障害の治療方法
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
JP2002502421A (ja) * 1997-06-05 2002-01-22 イーライ・リリー・アンド・カンパニー 血栓障害の処置方法
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1133314B1 (de) 1998-11-23 2003-02-19 Eli Lilly And Company Protein c zur behandlung von sichelzellanämie und thalassämie
AU2001238034A1 (en) * 2000-02-04 2001-08-14 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20040122354A1 (en) * 2002-09-05 2004-06-24 Semba Charles P. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1651252B1 (de) * 2003-07-08 2014-11-26 The Scripps Research Institute Aktivierte protein c varianten mit normaler zytoprotektiver aktivität aber verringerter gerinnungshemmender aktivität
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
EP2078074A4 (de) * 2006-10-31 2011-09-28 Scripps Research Inst Dosierplan für aktiviertes protein-c und varianten mit verminderter gerinnungshemmender wirkung
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
EP3539542B1 (de) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Verteilungsverbesserte verbindungen und ihre verwendung mit einem thrombolyticum
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
EP0156169B1 (de) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha Wässrige Lösung eines darin in erhöhter Konzentration aufgelösten Gewebe-Plasminogen-Aktivators und Herstellungsverfahren
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
DE3855096D1 (de) 1996-04-18
EP0318201A2 (de) 1989-05-31
EP0318201A3 (en) 1990-02-07
NO885109D0 (no) 1988-11-16
FI104790B (fi) 2000-04-14
GR3020036T3 (en) 1996-08-31
CA1330036C (en) 1994-06-07
DK640088A (da) 1989-05-18
US5350578A (en) 1994-09-27
JPH01238536A (ja) 1989-09-22
FI885331A0 (fi) 1988-11-17
US5084274A (en) 1992-01-28
JP2766986B2 (ja) 1998-06-18
ES2086301T3 (es) 1996-07-01
FI885331A (fi) 1989-05-18
DE3855096T2 (de) 1996-07-25
DK175704B1 (da) 2005-01-24
NO885109L (no) 1989-05-18
EP0318201B1 (de) 1996-03-13
NO301747B1 (no) 1997-12-08
DK640088D0 (da) 1988-11-16

Similar Documents

Publication Publication Date Title
ATE135234T1 (de) Hemmung von arteriellem thrombotischen verschluss oder von thrombo-embolismus
DK463989A (da) Farmaceutisk virksom kombination
DE3874798T2 (de) Therapeutisches proteinagens in form von aerosol.
ATE120206T1 (de) Peptide, die die bindung des von-willebrand- faktors inhibieren.
ATA123991A (de) Arzneimittel enthaltend aktiviertes protein c
ATE104151T1 (de) Trombosebehandlung mit fibrinolytika und prostacyclinen.
DE3880480T2 (de) Hemolyse-inhibitor und plastifizierungsmittel.
DE69110713T2 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DK627687D0 (da) Hirudinvariant
DE68905306D1 (de) Reinigung von alkansulfonsaeuren mit ozon.
DK50987D0 (da) Polypeptid med plasminogenaktivatorvirkning
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
DK491988A (da) Modificerede plasminogen-aktivatorer
DK213589D0 (da) Antistoffer mod fibrin og immunogen til brug ved fremstilling deraf
DK301589A (da) Laegemiddel med thrombolytisk virkning
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
MX174250B (es) Composicion con actividad antiagregante de plaqueta util en terapias
DK37988A (da) Fibrinolytisk vaevstype-plasminogenaktivator
EP0191814A4 (de) Absorptionsverbesserer für proteine.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee